Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Outpatient Extension Study to Evaluate the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

NCT05076617 is registered in ClinicalTrials.gov with UCB Biopharma SRL as lead sponsor.

NCT NCT05076617
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05076617 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Outpatient Extension Study to Evaluate the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
Lead sponsor
UCB Biopharma SRL
Phase
Phase 3
Overall status
Enrolling by invitation
Start date
February 3, 2022
Completion date
November 30, 2028
Enrollment
300 (estimated)
Sites
136

Conditions

As the registry lists them; a condition with its own page is linked.

stereotypical prolonged seizures